<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03986073</url>
  </required_header>
  <id_info>
    <org_study_id>TQ-F3083-II-01</org_study_id>
    <nct_id>NCT03986073</nct_id>
  </id_info>
  <brief_title>Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase IIA , Multi-center, Randomized, Double-blind, Placebo and Positive Drug Parallel Control Study of TQ-F3083 Capsules With Different Doses in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TQ-F3083 capsule is a new type inhibitor of DPP-IV, which is currently a very effective
      target for the treatment of type 2 diabetes mellitus at clinical. In addition, it can promote
      insulin secretion with low potential toxicity, and half-life is shorter than Linagliptin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycosylated hemoglobin (HbA1c)</measure>
    <time_frame>up to approximately 15 weeks</time_frame>
    <description>Changes in HbA1c compared with baseline after 12 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose (FPG)</measure>
    <time_frame>up to approximately 15 weeks</time_frame>
    <description>Changes in FPG compared with baseline after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 hours-postprandial blood sugar (2h-PPG）</measure>
    <time_frame>up to approximately 15 weeks</time_frame>
    <description>Changes in 2h-PPG compared with baseline after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>up to approximately 7, 11, 15 weeks</time_frame>
    <description>Changes in weight compared with baseline after 4, 8, 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>up to approximately 15 weeks</time_frame>
    <description>The proportion of patients with HbA1c less than 7% after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>up to approximately 15 weeks</time_frame>
    <description>The proportion of patients with HbA1c reduced at least 0.5% after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DPP-4 activity ( dipeptidyl peptidase-4)</measure>
    <time_frame>baseline up to 4, 8, 12 weeks</time_frame>
    <description>changes in DPP-4 activity compared with baseline after 4, 8, 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLP-1 (glucagon-like peptide-1)</measure>
    <time_frame>baseline up to 4, 8, 12 weeks</time_frame>
    <description>changes in DPP-4 activity GLP-1 concentrations compared with baseline after 4, 8, 12 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the low dose group administrated one TQ-F3083 capsule 10mg, one TQ-F3083 blank analog capsule and one Linagliptin blank analog tablet orally, once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the high dose group administrated twoTQ-F3083 capsules 20mg and one Linagliptin blank analog tablet orally, once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive drug control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in the positive drug control group administrated two TQ-F3083 blank analog capsules and one Linagliptin tablet orally, once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in the placebo group administrated two TQ-F3083 blank analog capsules and one Linagliptin blank analog tablet orally, once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-F3083 capsule 10 mg</intervention_name>
    <description>Subjects in the low dose group administrated TQ-F3083 capsule 10mg, once daily for 12 weeks.</description>
    <arm_group_label>Low dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-F3083 capsule 20 mg</intervention_name>
    <description>Subjects in the high dose group administrated TQ-F3083 capsule 20 mg, once daily for 12 weeks.</description>
    <arm_group_label>High dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-F3083 blank analog capsule</intervention_name>
    <description>Subjects administrated one TQ-F3083 blank analog capsule orally, once daily for 12 weeks.</description>
    <arm_group_label>Low dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-F3083 blank analog capsule</intervention_name>
    <description>Subjects administrated two TQ-F3083 blank analog capsules orally, once daily for 12 weeks.</description>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_label>Positive drug control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin blank analog tablet</intervention_name>
    <description>Subjects administrated one Linagliptin blank analog tablet orally, once daily for 12 weeks.</description>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin tablet</intervention_name>
    <description>Subjects in the positive drug control group administrated one Linagliptin tablet orally, once daily for 12 weeks.</description>
    <arm_group_label>Positive drug control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Understood and signed an informed consent form; 2.18 and 70 years old; 3.Body mass index
        (BMI) of 19 to 37.5 kg/m2; 4.Type 2 diabetes mellitus confirmed at least 6 weeks before
        screen by WHO (1999) diabetes mellitus diagnostic criteria; 5.Has inadequate glycemic
        control on diet/exercise therapy and irregular use hypoglycemic agents before screening,
        HbA1c ≥7.0% and ≤10.0% ; Has regular hypoglycemic agents with stable dose within 6 weeks
        before screening, HbA1c ≥7.0% and ≤9 %; 6.PFG ≤ 13.3 mmol / L; 7. Adequate laboratory
        inspection standards.

        Exclusion Criteria:

          1. Has any contraindications, allergies or hypersensitivity for taking research
             medication ;

          2. Has used at lest two oral medications to treat diabetes mellitus 6 weeks before
             screening;

          3. Has other endocrine-related history or evidence before screening;

          4. Has history of organ transplantation;

          5. Has mental or neurological diseases;

          6. Has received systemic corticosteroids within 2 weeks;

          7. Has received GLP-1 analogues, DPP-4 inhibitors or anti-obesity drugs 3 months ;

          8. Has alcohol abuse history within 6 months before screening;

          9. Has participated in any clinical trial within 3 months;

         10. Has received blood transfusions, or blood donation ≥ 400 mL , or got severe blood loss
             ≥ 400 mL within 8 weeks;

         11. Pregnant or lactating woman.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nanwei Tong, Doctor</last_name>
    <phone>18980601196</phone>
    <email>tongnw@scu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Chongqing Medical Uversity</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gangyi Yang, Doctor</last_name>
      <email>gangyiyang@163.com</email>
    </contact>
    <investigator>
      <last_name>Gangyi Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chongqing General Hospital, UCAS</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Song Lu, Bachelor</last_name>
      <email>1516zzy@163.com</email>
    </contact>
    <investigator>
      <last_name>Song Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bin Yao, Master</last_name>
      <email>Bin@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Bin Yao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hong Liu, Master</last_name>
      <email>Hongmm1@qq.com</email>
    </contact>
    <investigator>
      <last_name>Hong Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Minxiang Lei, Doctor</last_name>
      <email>xyyynfm618@163.com</email>
    </contact>
    <investigator>
      <last_name>Minxiang Lei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yuncheng Central Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaolin Dong, Doctor</last_name>
      <email>13869123309@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaolin Dong, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jincheng Geberal Hospital</name>
      <address>
        <city>Jincheng</city>
        <state>Shanxi</state>
        <zip>048000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lili Zhang, Doctor</last_name>
      <email>2366787060@qq.com</email>
    </contact>
    <investigator>
      <last_name>Lili Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nanwei Tong, Doctor</last_name>
      <email>tongnw@scu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Nanwei Tong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Yunnan Province</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heng Su, Doctor</last_name>
      <email>Su_hen@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Heng Su</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 9, 2019</study_first_submitted>
  <study_first_submitted_qc>June 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2019</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

